ELVN logo

Enliven Therapeutics, Inc. (ELVN) Cash From Operations

Annual CFO:

-$73.19M-$11.92M(-19.46%)
December 31, 2024

Summary

  • As of today, ELVN annual cash from operations is -$73.19 million, with the most recent change of -$11.92 million (-19.46%) on December 31, 2024.
  • During the last 3 years, ELVN annual cash from operations has fallen by -$54.06 million (-282.52%).
  • ELVN annual cash from operations is now -733.91% below its all-time high of -$8.78 million, reached on December 1, 2018.

Performance

ELVN Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNcash flow metrics

Quarterly CFO:

-$13.28M+$3.78M(+22.15%)
September 30, 2025

Summary

  • As of today, ELVN quarterly cash from operations is -$13.28 million, with the most recent change of +$3.78 million (+22.15%) on September 30, 2025.
  • Over the past year, ELVN quarterly cash from operations has dropped by -$1.09 million (-8.91%).
  • ELVN quarterly cash from operations is now -105.97% below its all-time high of -$6.45 million, reached on September 30, 2022.

Performance

ELVN Quarterly Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNcash flow metrics

TTM CFO:

-$71.67M-$1.09M(-1.54%)
September 30, 2025

Summary

  • As of today, ELVN TTM cash from operations is -$71.67 million, with the most recent change of -$1.09 million (-1.54%) on September 30, 2025.
  • Over the past year, ELVN TTM cash from operations has dropped by -$3.19 million (-4.67%).
  • ELVN TTM cash from operations is now -652.24% below its all-time high of -$9.53 million, reached on March 1, 2020.

Performance

ELVN TTM Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNcash flow metrics

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

ELVN Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-19.5%-8.9%-4.7%
3Y3 Years-282.5%-106.0%-96.8%
5Y5 Years-234.6%-28.4%-91.6%

ELVN Cash From Operations Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-282.5%at low-106.0%+45.0%-101.5%+3.1%
5Y5-Year-282.5%at low-106.0%+45.0%-101.5%+3.1%
All-TimeAll-Time-733.9%at low-106.0%+45.0%-652.2%+3.1%

ELVN Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2025
-
-$13.28M(+22.1%)
-$71.67M(-1.5%)
Jun 2025
-
-$17.06M(+29.3%)
-$70.58M(+4.6%)
Mar 2025
-
-$24.13M(-40.2%)
-$73.96M(-1.0%)
Dec 2024
-$73.19M(-19.5%)
-$17.20M(-41.1%)
-$73.19M(-6.9%)
Sep 2024
-
-$12.19M(+40.3%)
-$68.47M(+5.1%)
Jun 2024
-
-$20.43M(+12.5%)
-$72.17M(-13.1%)
Mar 2024
-
-$23.36M(-87.2%)
-$63.79M(-4.1%)
Dec 2023
-$61.27M(-72.3%)
-$12.48M(+21.5%)
-$61.27M(-1.4%)
Sep 2023
-
-$15.89M(-31.9%)
-$60.42M(-18.5%)
Jun 2023
-
-$12.05M(+42.2%)
-$50.98M(-10.7%)
Mar 2023
-
-$20.84M(-79.1%)
-$46.05M(-29.5%)
Dec 2022
-$35.57M
-$11.64M(-80.5%)
-$35.57M(+2.3%)
Sep 2022
-
-$6.45M(+9.5%)
-$36.42M(+10.9%)
DateAnnualQuarterlyTTM
Jun 2022
-
-$7.12M(+31.2%)
-$40.87M(+7.3%)
Mar 2022
-
-$10.36M(+17.0%)
-$44.11M(+5.7%)
Dec 2021
-$19.13M(+48.8%)
-
-
Dec 2021
-
-$12.48M(-14.5%)
-$46.77M(-9.9%)
Sep 2021
-
-$10.90M(-5.2%)
-$42.55M(-1.3%)
Jun 2021
-
-$10.37M(+20.4%)
-$42.00M(-2.7%)
Mar 2021
-
-$13.02M(-57.5%)
-$40.89M(-9.3%)
Dec 2020
-$37.40M(-70.9%)
-$8.27M(+20.1%)
-$37.40M(-28.4%)
Sep 2020
-
-$10.35M(-11.8%)
-$29.13M(-55.1%)
Jun 2020
-
-$9.26M(+2.8%)
-$18.78M(-97.2%)
Mar 2020
-
-$9.53M
-$9.53M
Dec 2019
-$21.88M(-149.3%)
-
-
Dec 2018
-$8.78M(+0.1%)
-
-
Dec 2017
-$8.79M
-
-

FAQ

  • What is Enliven Therapeutics, Inc. annual cash from operations?
  • What is the all-time high annual cash from operations for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. annual cash from operations year-on-year change?
  • What is Enliven Therapeutics, Inc. quarterly cash from operations?
  • What is the all-time high quarterly cash from operations for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. quarterly cash from operations year-on-year change?
  • What is Enliven Therapeutics, Inc. TTM cash from operations?
  • What is the all-time high TTM cash from operations for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. TTM cash from operations year-on-year change?

What is Enliven Therapeutics, Inc. annual cash from operations?

The current annual cash from operations of ELVN is -$73.19M

What is the all-time high annual cash from operations for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high annual cash from operations is -$8.78M

What is Enliven Therapeutics, Inc. annual cash from operations year-on-year change?

Over the past year, ELVN annual cash from operations has changed by -$11.92M (-19.46%)

What is Enliven Therapeutics, Inc. quarterly cash from operations?

The current quarterly cash from operations of ELVN is -$13.28M

What is the all-time high quarterly cash from operations for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high quarterly cash from operations is -$6.45M

What is Enliven Therapeutics, Inc. quarterly cash from operations year-on-year change?

Over the past year, ELVN quarterly cash from operations has changed by -$1.09M (-8.91%)

What is Enliven Therapeutics, Inc. TTM cash from operations?

The current TTM cash from operations of ELVN is -$71.67M

What is the all-time high TTM cash from operations for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high TTM cash from operations is -$9.53M

What is Enliven Therapeutics, Inc. TTM cash from operations year-on-year change?

Over the past year, ELVN TTM cash from operations has changed by -$3.19M (-4.67%)
On this page